Merck (MRK) Presents Results from Three MK-3682B Phase 2s; High SVR Rates Noted
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/16/2024
- Wall Street stocks close lower on higher Treasury yields, rate expectations
- Powell says recent inflation data point to need to keep rates higher for longer
- United Airlines maintains forecast after Q1 results top Wall Street estimates
- UnitedHealth (UNH) beats earnings, revenue estimates in Q1; shares up
- Bank of America profit hurt by losses on credit cards, office loans
- Trump Media & Technology Group (DJT) Files S-1
- Tesla (TSLA) Senior VP Drew Baglino Is Said To Leave The Company - Bloomberg
- GE HealthCare (GEHC) Announces Resignation of Jan Makela, CEO of Imaging
- General Motors (GM) Said to be Moving Detroit HQ to Dan Gilbert's Hudson Tower - Bloomberg
- Biohaven Pharma (BHVN) presents update on degrader platform and summary of progress to date in Phase 1 single ascending dose study for BHV-1300
- After-hours movers: United Airlines, J.B. Hunt, and more
- Midday movers: Morgan Stanley, UnitedHealth rise; Tesla falls
- Morgan Stanley, UnitedHealth and Bank of America rise premarket; Tesla falls
- After-hours movers: Tesla, Gildan Activewear, Macatawa Bank, and more
- Midday movers: Goldman Sachs and Meta Platforms rise; Apple and Tesla fall
Merck (MRK) Announces Upcoming Presentation of Strong ZEPATIER Data in Certain HCV Genotypes
November 14, 2016 6:52 AM ESTMerck (NYSE: MRK) announced results from multiple analyses at The Liver Meeting® 2016, which provide additional evidence supporting the use of ZEPATIER (elbasvir and grazoprevir) 50mg/100mg tablets in chronic hepatitis C virus (HCV) genotype (GT) 1- or GT4-infected patient... More
